#337 - Insulin resistance masterclass: The full body impact of metabolic dysfunction and prevention, diagnosis, and treatment | Ralph DeFronzo, M.D.
Dr. Ralph DeFronzo, a distinguished diabetes researcher and clinician, provides a masterclass on type 2 diabetes, detailing the "ominous octet" of organ-specific defects. He discusses the pharmacology of current and past treatments, emphasizing combination therapy and the underappreciated benefits of certain drugs.
Deep Dive Analysis
19 Topic Outline
Introduction to Metabolic Disease and Insulin Resistance
Defining Insulin Resistance and the Euglycemic Clamp Technique
Tissue-Specific Effects of Insulin and Insulin Resistance
Hyperinsulinemia Induces Insulin Resistance
Challenges in Identifying the Genetic Basis of Insulin Resistance
The Ominous Octet: A Comprehensive Model of Type 2 Diabetes
Role of Adipose Tissue and Lipotoxicity in Insulin Resistance
The Gut: Incretin Hormones and Beta Cell Dysfunction
The Alpha Cell and Hyperglucagonemia
The Kidney's Role and Development of SGLT2 Inhibitors
The Brain: Neurocircuitry Dysfunction and Appetite Regulation
Pioglitazone: An Underappreciated Insulin Sensitizer
Metformin: Mechanism of Action and Misconceptions
Optimal Triple Therapy vs. ADA Approach for Diabetes Management
GLP-1 Agonists: Beta Cell Preservation and Weight Loss
Myostatin Inhibitors and Functional Outcomes of Muscle Mass
The Crisis of Childhood Obesity and Diabetes
Environmental and Neurological Factors Driving Obesity
Early Detection of Diabetes Risk with Oral Glucose Tolerance Test
6 Key Concepts
Insulin Resistance
A condition where the body's cells do not respond effectively to insulin, leading to impaired uptake and utilization of glucose by muscles, reduced inhibition of fat release from fat cells, and decreased suppression of glucose production by the liver. It's a general term because insulin controls many biochemical processes, and resistance can manifest differently across various tissues and metabolic pathways.
Euglycemic Clamp Technique
The gold standard method for measuring insulin sensitivity, developed by Dr. DeFronzo. It involves infusing insulin at a constant rate while simultaneously infusing glucose to maintain a stable, normal blood sugar level (euglycemia). The amount of glucose required to maintain euglycemia directly reflects the body's sensitivity to insulin, with higher glucose infusion rates indicating greater insulin sensitivity.
Lipotoxicity
A state where high levels of free fatty acids (FFA) in the bloodstream, often resulting from insulin-resistant fat cells releasing excessive fat, become toxic to other tissues. These high FFA levels impair insulin secretion by beta cells, cause insulin resistance in muscle and liver, and disrupt the insulin signaling pathway, contributing significantly to type 2 diabetes.
Glucotoxicity
The damaging effect of chronically high blood glucose levels on various tissues, particularly the beta cells of the pancreas. Sustained hyperglycemia can impair beta cell function, making them less responsive to signals like GIP (glucose-dependent insulinotropic polypeptide) and further exacerbating insulin secretion defects in type 2 diabetes.
Ominous Octet
An expanded model of the pathophysiology of type 2 diabetes, developed by Dr. DeFronzo, which identifies eight key organ defects contributing to the disease. It builds upon the traditional 'triumvirate' (beta cell failure, muscle insulin resistance, liver insulin resistance) by adding defects in fat cells, the gastrointestinal tract (incretin effect), alpha cells (hyperglucagonemia), kidneys (glucose reabsorption), and the brain (appetite regulation).
First-Phase Insulin Secretion
The rapid, initial burst of insulin released by pancreatic beta cells immediately following a sudden increase in blood glucose, such as after a meal. This early insulin response is crucial for quickly suppressing hepatic glucose production and promoting glucose uptake. Its impairment is one of the earliest detectable defects in individuals predisposed to type 2 diabetes.
8 Questions Answered
Insulin resistance impairs glucose uptake and burning by muscles, reduces insulin's ability to keep fat stored in fat cells (leading to fat release), and diminishes insulin's capacity to shut down glucose production by the liver.
Hyperinsulinemia directly induces insulin resistance by down-regulating the insulin signaling transduction system within cells. Studies showed that raising fasting insulin levels from 8 to 20 microunits/mL in healthy lean individuals for 48-72 hours made them as insulin resistant as type 2 diabetics.
The 'ominous octet' expands on the traditional 'triumvirate' by identifying eight key defects: beta cell failure, insulin resistance in muscle, insulin resistance in the liver, fat cell dysfunction (excessive fat release), gastrointestinal incretin hormone deficiency/resistance, alpha cell hyperglucagonemia, increased renal glucose reabsorption, and brain insulin resistance/neurocircuitry dysfunction affecting appetite.
Pioglitazone is the only true insulin sensitizer, correcting the insulin signaling defect and improving mitochondrial function. Despite causing some weight gain (often fat redistribution) and fluid retention (due to vasodilation), studies show it significantly improves myocardial blood flow, insulin sensitivity in heart and muscle, ejection fraction, and reduces cardiovascular events.
No, metformin is not a true insulin sensitizer. Its primary mechanism of action is reducing hepatic glucose output by inhibiting gluconeogenesis, likely by interfering with the mitochondrial chain in the liver. It cannot enter muscle or cardiac cells due to the absence of the organic cation transporter.
Optimal treatment involves combination therapy from the outset, typically using a GLP-1 receptor agonist, pioglitazone, and an SGLT2 inhibitor, potentially with metformin. This approach addresses multiple pathophysiological defects simultaneously, leading to significantly better glucose control and improved insulin sensitivity and beta cell function compared to the traditional stepwise ADA approach.
While highly effective for weight loss and beta cell preservation, concerns include gastrointestinal side effects, cost, and the loss of muscle mass alongside fat. Although studies suggest functional improvements (e.g., strength per body weight, walking distance) despite absolute muscle loss, ongoing research is exploring ways to mitigate muscle loss.
A one-hour glucose level greater than 155 mg/dL during an OGTT is the best predictor of who will develop type 2 diabetes, regardless of other metrics. Additionally, a low insulin response in the first 30 minutes of the OGTT (reflecting loss of first-phase insulin secretion) is another strong predictor of future trouble.
27 Actionable Insights
1. Precision Diabetes Care
Physicians should adopt a precision medicine approach to type 2 diabetes by identifying the specific phenotype of each patient, rather than treating it as a single, uniform disease, to provide optimal care.
2. Start Combination Therapy Early
Consider starting combination therapy for type 2 diabetes from the outset, as recommended by the American Diabetes Association, rather than a stepwise approach, to address the multiple underlying pathophysiological defects.
3. Optimal Diabetes Drug Regimen
For optimal type 2 diabetes treatment, if cost is not a barrier, prioritize a newer GLP-1 agonist as a foundational drug, add pioglitazone for insulin sensitization, and an SGLT2 inhibitor as a third, especially if there is renal or cardiac disease.
4. Cost-Effective Diabetes Therapy
For effective type 2 diabetes management, consider a triple therapy approach using older, affordable drugs like metformin, exenatide (an older GLP-1 agonist), and pioglitazone, as this combination has shown significant improvements in A1C, insulin sensitivity, and beta cell function.
5. Utilize Pioglitazone (Actos)
Consider pioglitazone (Actos) as a true insulin sensitizer to correct insulin signaling defects and redistribute fat from organs like muscle, liver, and beta cells to subcutaneous tissue, improving overall metabolic health.
6. SGLT2 for Primary Prevention
Consider using SGLT2 inhibitors in newly diagnosed diabetics without existing cardiac symptoms for primary prevention of cardiovascular and renal disease, based on their documented benefits in secondary prevention.
7. GLP-1s Boost Beta Cells
Recognize that GLP-1 agonists are powerful for improving and preserving beta cell function in type 2 diabetes, not just for weight loss, and this effect is crucial for long-term disease management.
8. Reduce Insulin Dosage Physiologically
If you have type 2 diabetes and are taking high doses of insulin (e.g., 75 units/day), aim to reduce it to a more physiological level (around 35 units/day) through nutrition, exercise, and other pharmacological interventions.
9. Avoid Chronic Hyperinsulinemia
Avoid chronic hyperinsulinemia, as it can down-regulate the insulin signaling system and induce insulin resistance, making the condition worse.
10. Implement Lifestyle Changes
Implement lifestyle changes such as weight loss and exercise, alongside appropriate medications (insulin sensitizers or weight-loss drugs), to effectively reduce insulin dosage in individuals with type 2 diabetes.
11. Address Childhood Obesity
Recognize childhood obesity as a critical public health concern leading to early-onset, aggressive type 2 diabetes that is often resistant to conventional treatments, necessitating early and aggressive intervention strategies.
12. Tackle Obesity’s Root Causes
Address the obesity epidemic by tackling multiple contributing factors, including processed and calorically dense foods, lack of exercise, and the resulting changes in brain neurocircuitry related to food intake.
13. OGTT: One-Hour Glucose Predictor
Pay close attention to the one-hour glucose level during an Oral Glucose Tolerance Test (OGTT); a reading greater than 155 mg/dL is a strong predictor of developing type 2 diabetes, regardless of other metrics.
14. OGTT: Hypoglycemia Indicates Resistance
If an OGTT shows a high insulin response at 30 minutes followed by hypoglycemia at two hours, it indicates a pre-diabetic state with significant insulin resistance and an overshooting beta cell response.
15. OGTT: Delayed Insulin Response
A low insulin response at 30 minutes during an OGTT, indicating a loss of first-phase insulin secretion, is a predictor of a primary beta cell defect and future type 2 diabetes development.
16. Measure C-Peptide, Not Insulin
To accurately assess insulin secretion, measure C-peptide levels rather than insulin levels, as C-peptide is not taken up by the liver and thus provides a more reliable measure of pancreatic beta cell output.
17. Understand Tissue-Specific Resistance
When discussing or assessing insulin resistance, specify the affected tissue (e.g., muscle, liver, fat cell, brain) and the particular metabolic process, as insulin’s actions vary across tissues.
18. Embrace Pioglitazone Weight Gain
Do not be deterred by weight gain when using pioglitazone, as studies show that greater weight gain with this drug correlates with improved A1C, insulin sensitivity, beta cell function, blood pressure, triglycerides, and HDL cholesterol due to fat redistribution.
19. Pioglitazone for NASH
Consider pioglitazone (Actos) as the best drug for treating Non-Alcoholic Steatohepatitis (NASH) due to its fat redistribution effects.
20. Pioglitazone Cardiovascular Benefit
Recognize that pioglitazone has demonstrated cardiovascular safety and benefit, with weight gain on the drug paradoxically correlating with reduced mortality in the PROactive study.
21. Metformin: Cost-Effective Addition
Utilize metformin as a cost-effective foundational drug in combination therapy for type 2 diabetes, as it is inexpensive and can be safely added to other medications.
22. Metformin Not Muscle Sensitizer
Understand that metformin primarily reduces hepatic glucose output by inhibiting gluconeogenesis and does not directly improve insulin sensitivity in muscle, as it cannot enter muscle cells.
23. GLP-1 Adherence is Key
When prescribing powerful new drugs like GLP-1 agonists for severe type 2 diabetes, ensure patient adherence, affordability, and proper medical guidance, as these factors are critical for sustained success and preventing relapse.
24. Re-Listen to This Podcast
Listen to this podcast episode with Dr. Ralph DeFranzo multiple times to fully grasp the complex information on type 2 diabetes and insulin resistance.
25. Listen to Shulman Episode
Listen to Peter Attia’s previous podcast episode with Jerry Shulman to understand insulin resistance, particularly its manifestation in muscle.
26. Sophisticated Beta Cell Testing
For precise assessment of beta cell function in a research or specialized clinical setting, consider advanced techniques like a three-step hyperglycemic clamp followed by sequential infusions of GLP-1 and amino acids to measure specific responses to different stimuli.
27. Support Peter Attia’s Content
Become a premium member of Peter Attia’s podcast/website for advanced health and wellness knowledge and exclusive content, as it’s designed to provide value exceeding the subscription cost.
6 Key Quotes
If you are insulin resistant and your beta cells work well, they know how to read the insulin resistance. They'll make enough insulin. You won't become diabetic. The hyperinsulinemia can damage you in other ways, but you won't become diabetic.
Ralph DeFronzo
If I raise the insulin just by 10 micro units per ml, the fat stops producing free fatty acids and glycerol. You inhibit lipolysis literally completely.
Ralph DeFronzo
Hyperinsulinemia induces insulin resistance.
Ralph DeFronzo
Metformin is not an insulin sensitizer. And people keep going back to this. I brought metformin to the US in 1995. I know this. I did all the mechanism of action studies. What we showed was the insulin clamp. The drug absolutely does not improve insulin sensitivity.
Ralph DeFronzo
I jokingly say, look, you can either be a little fat and alive, or you can be lean and dead. Which one are you going to pick? I think I go for being a little bit chubby.
Ralph DeFronzo
If you tied my hands behind my back and said, Ralph, you can only pick one drug, I would pick one of the newer GLP-1s. They're incredible drugs.
Ralph DeFronzo
4 Protocols
Euglycemic Clamp Technique (for measuring insulin sensitivity)
Ralph DeFronzo- Infuse insulin as a prime dose, then continuously to clamp insulin level (e.g., raise by 100 microunits/mL).
- Maintain fasting glucose (e.g., 80 mg/dL) by simultaneously infusing glucose.
- Measure glucose uptake/disposal by muscle (e.g., 80-90% of glucose taken up).
- Measure inhibition of hepatic glucose production (e.g., insulin shuts it down quickly in normal people).
- Measure inhibition of fat release (lipolysis) from fat cells.
Triple Therapy for Type 2 Diabetes (EDICS Study Approach)
Ralph DeFronzo- Initiate with Metformin.
- Add Exenatide (an older GLP-1 agonist).
- Add Pioglitazone (a true insulin sensitizer).
- Goal: Achieve and maintain A1C less than 6.5%.
ADA Stepwise Approach for Type 2 Diabetes (Treat-to-Fail)
Ralph DeFronzo- Start with Metformin.
- If Metformin fails, add a Sulfonylurea.
- If Sulfonylurea fails, add Insulin (basal insulin titrated up to 60 units, then rapid-acting insulin).
- Goal: Achieve A1C of 6.5%.
Triple Stimuli Hyperglycemic Clamp (for beta cell function genetics)
Ralph DeFronzo- Perform a three-step hyperglycemic clamp to measure beta cell sensitivity to glucose (by C-peptide response to glucose rises).
- Following the clamp, infuse GLP-1 and measure insulin/C-peptide response.
- After GLP-1, infuse a balanced amino acid solution and measure insulin/C-peptide response.
- Analyze different genetic loci associated with defects in response to each specific stimulus.